| [1] |
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024[J]. CA Cancer J Clin, 2024, 74(1): 12-49. DOI: 10.3322/caac.21820.
|
| [2] |
Liu X, Yu C, Bi Y, et al. Trends and age-period-cohort effect on incidence and mortality of prostate cancer from 1990 to 2017 in China[J]. Public Health, 2019, 172: 70-80. DOI: 10.1016/j.puhe.2019.04.016.
pmid: 31220754
|
| [3] |
Emam A, Hermann G, Attwood K, et al. Oncologic outcome of radical prostatectomy versus radiotherapy as primary treatment for high and very high risk localized prostate cancer[J]. Prostate, 2021, 81(4): 223-230. DOI: 10.1002/pros.24089.
pmid: 33471385
|
| [4] |
Kim WT, Kim J, Kim WJ. How can we best manage biochemical failure after radical prostatectomy?[J]. Investig Clin Urol, 2022, 63(6): 592-601. DOI: 10.4111/icu.20220294.
pmid: 36347548
|
| [5] |
那彦群, 叶章群, 孙颖浩, 等. 2014版中国泌尿外科疾病诊断治疗指南[M] 北京: 人民卫生出版社, 2013.
|
| [6] |
Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013[J]. Eur Urol, 2014, 65(1): 124-137. DOI: 10.1016/j.eururo.2013.09.046.
pmid: 24207135
|
| [7] |
Mottet N, Bergh R, Briers E, et al. EAU-ESTRO-SIOG guidelines on prostate cancer[M]. Arnhem, the Netherlands: European Association of Urology, 2018: 1-146.
|
| [8] |
Tilki D, Chen MH, Wu J, et al. Persistent prostate-specific antigen following radical prostatectomy for prostate cancer and mortality risk[J]. JAMA Oncol, 2025, 11(5): 502-510. DOI: 10.1001/jamaoncol.2025.0110.
pmid: 40080000
|
| [9] |
Roberts MJ, Papa N, Veerman H, et al. Prediction of biochemical recurrence after radical prostatectomy from primary tumour characte-ristics[J]. BJU Int, 2024, Suppl 2(Suppl 2): 47-55. DOI: 10.1111/bju.16482.
|
| [10] |
McCormick BZ, Mahmoud AM, Williams SB, et al. Biochemical recurrence after radical prostatectomy: current status of its use as a treatment endpoint and early management strategies[J]. Indian J Urol, 2019, 35(1): 6-17. DOI: 10.4103/iju.IJU_355_18.
|
| [11] |
Takeda H, Akatsuka J, Yuki E, et al. Long-term oncological outcomes for histologically confirmed high-risk prostate cancer[J]. J Nippon Med Sch, 2023, 90(2): 202-209. DOI: 10.1272/jnms.JNMS.2023_90-210.
|
| [12] |
Sood A, Grauer R, Diaz-Insua M, et al. 15-year biochemical failure, metastasis, salvage therapy, and cancer-specific and overall survival rates in men treated with robotic radical prostatectomy for PSA-screen detected prostate cancer[J]. Prostate Cancer Prostatic Dis, 2023, 26(4): 778-786. DOI: 10.1038/s41391-023-00674-2.
|
| [13] |
Moris L, Cumberbatch MG, Van den Broeck T, et al. Benefits and risks of primary treatments for high-risk localized and locally advanced prostate cancer: an international multidisciplinary systematic review[J]. Eur Urol, 2020, 77(5): 614-627. DOI: 10.1016/j.eururo.2020.01.033.
pmid: 32146018
|
| [14] |
Matsumoto K, Niwa N, Hagiwara M, et al. Long-term follow-up comparing salvage radiation therapy and androgen-deprivation therapy for biochemical recurrence after radical prostatectomy[J]. Int J Clin Oncol, 2021, 26(4): 744-752. DOI: 10.1007/s10147-020-01839-y.
pmid: 33387085
|
| [15] |
Marra G, Valerio M, Heidegger I, et al. Management of patients with node-positive prostate cancer at radical prostatectomy and pelvic lymph node dissection: a systematic review[J]. Eur Urol Oncol, 2020, 3(5): 565-581. DOI: 10.1016/j.euo.2020.08.005.
pmid: 32933887
|
| [16] |
Efstathiou E, Davis JW, Pisters L, et al. Clinical and biological characterisation of localised high-risk prostate cancer: results of a randomised preoperative study of a luteinising hormone-releasing hormone agonist with or without abiraterone acetate plus prednisone[J]. Eur Urol, 2019, 76(4): 418-424. DOI: 10.1016/j.eururo.2019.05.010.
pmid: 31176622
|
| [17] |
Preisser F, Coxilha G, Heinze A, et al. Impact of positive surgical margin length and Gleason grade at the margin on biochemical recurrence in patients with organ-confined prostate cancer[J]. Prostate, 2019, 79(16): 1832-1836. DOI: 10.1002/pros.23908.
pmid: 31553506
|
| [18] |
Omri N, Kamil M, Alexander K, et al. Association between PSA density and pathologically significant prostate cancer: the impact of prostate volume[J]. Prostate, 2020, 80(16): 1444-1449. DOI: 10.1002/pros.24078.
|
| [19] |
王方明, 韩苏军, 杨飞亚, 等. 高危前列腺癌腹腔镜根治性前列腺切除术后切缘阳性的危险因素[J]. 中华泌尿外科杂志, 2021, 42(5): 349-354. DOI: 10.3760/cma.j.cn112330-20201013-00716.
|
| [20] |
Martini A, Gandaglia G, Fossati N, et al. Defining clinically mea-ningful positive surgical margins in patients undergoing radical prostatectomy for localised prostate cancer[J]. Eur Urol Oncol, 2021, 4(1): 42-48. DOI: 10.1016/j.euo.2019.03.006.
|
| [21] |
McKay RR, Xie W, Ye H, et al. Results of a randomized phase Ⅱ trial of intense androgen deprivation therapy prior to radical prostatectomy in men with high-risk localized prostate cancer[J]. J Urol, 2021, 206(7): 80-87. DOI: 10.1097/JU.0000000000001702.
|